Sahdev Saharan, M.D., INC.

Sahdev Saharan, M.D., INC. was paid $20.02M by Medicaid between Jan 2018 and Dec 2024, across 24 billing codes. Its largest line is J0129, Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) — 37% of everything it billed.

33Billing provider infoSAHDEV SAHARAN, M.D., INC.
STOCKTON, CA 95204

33aNPI1174822902assigned 03/18/2011

33bProvider typeRheumatology Physician

28Total paid$20.02M

24GClaims42,362

24DCodes billed24

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other Rheumatology Physician providers in California

Rank by total paid#4 of 147

Median peer was paid$43K

This provider vs. median462×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	1,637	$583K
2019	4,377	$1.49M
2020	6,886	$3.07M
2021	6,436	$3.89M
2022	7,610	$3.72M
2023	8,686	$4.03M
2024incomplete	6,730	$3.24M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	37%	2,698	2,444	$7.38M
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	35%	3,806	3,502	$6.93M
J1602	Injection, golimumab, 1 mg, for intravenous use	11%	3,346	1,700	$2.28M
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	4.8%	12,380	12,049	$962K
J0491	Injection, anifrolumab-fnia, 1 mg	4.3%	268	251	$862K
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	2.4%	5,046	4,683	$482K
96401		1.8%	3,245	2,967	$369K
J0490	Injection, belimumab, 10 mg	1.6%	144	99	$321K
99244	Office or other outpatient consultation, moderate to high complexity	1.1%	1,398	1,395	$226K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	<1%	2,005	1,927	$118K
99204	Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity	<1%	998	993	$30K
20610		<1%	339	314	$15K

12 more codes

J1040	Injection, methylprednisolone acetate, 80 mg	<1%	1,519	$13K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	1,430	$11K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	897	$11K
96375	Therapeutic injection; each additional sequential IV push	<1%	603	$7K
96415		<1%	60	$3K
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	437	$1K
J1020	Injection, methylprednisolone acetate, 20 mg	<1%	12	$35.13
3075F		0%	142	$0.00
3074F		0%	676	$0.00
3079F		0%	290	$0.00
3080F		0%	25	$0.00
3078F		0%	598	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSAHARAN, SAHDEV (PRESIDENT)